0.3906  -0.011 (-2.79%)		08-21 16:00
Open: 0.4041 High: 0.4149 Volume: 50,810		Pre. Close: 0.4018 Low: 0.3906 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	0.48	1-year :	0.58
Resists	First :	0.41	Second :	0.49
Pivot price	0.4
Supports	First :	0.28	Second :	0.24
MAs	MA(5) :	0.42	MA(20) :	0.38
	MA(100) :	0.87	MA(250) :	2.72
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	53.6	D(3) :	63.5
RSI	RSI(14): 43.5
52-week	High :	17.39	Low :	0.28

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ FEED ] has closed above bottom band by 38.5%. Bollinger Bands are 74.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 85 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.42 - 0.42	0.42 - 0.42
Low:	0.38 - 0.39	0.39 - 0.39
Close:	0.39 - 0.39	0.39 - 0.39

NanoVibronix, Inc. focuses on developing non-surgical medical devices that stimulate biological responses. Its core offerings include UroShield and PainShield. The company's business activities span across several global markets, such as the United States, Europe, Australia, India, and Israel, in addition to other territories. This enterprise was founded by Harold Jacob and Jona Zumeris in September 2003, and its main corporate office is situated in Tyler, Texas.

Mon, 17 Aug 2026
ENvue Medical, Inc. 2026: Revenue $239K, EPS ($1.98) — 10-Q Summary - TradingView

Mon, 17 Aug 2026
ENvue Medical (FEED) raises going-concern doubt, adds equity facility - Stock Titan

Wed, 04 Feb 2026
Envue Medical: Bank of America sells $8.9k in stock - Investing.com

Thu, 29 Jan 2026
Nanovibronix (FEED) Stock Price, News & Analysis $FEED - MarketBeat

Thu, 24 Apr 2025
Nanovibronix (NAOV) Stock Price, News & Analysis - Stock Titan

Wed, 23 Aug 2023
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Specialties
Shares Out	9 (M)
Shares Float	6 (M)
Held by Insiders	20.9 (%)
Held by Institutions	0.7 (%)
Shares Short	162 (K)
Shares Short P.Month	410 (K)

EPS	-3.68
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	8.64
Profit Margin	0 %
Operating Margin	-568.3 %
Return on Assets (ttm)	-20.3 %
Return on Equity (ttm)	-59.5 %
Qtrly Rev. Growth	-36.3 %
Gross Profit (p.s.)	-0.03
Sales Per Share	0.23
EBITDA (p.s.)	-1.35
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	-0.11
PEG Ratio	0
Price to Book value	0.04
Price to Sales	1.66
Price to Cash Flow	-0.3

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.